Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mobius Therapeutics
St. Louis, Missouri, United States
- Ownership
- Public · MMIT
- Employees
- ~9
- Development stage
- Other
01
Overview
Mobius Therapeutics commercializes Mitosol (mitomycin for solution), the only FDA-approved formulation of mitomycin-c for ophthalmic use, considered the gold standard adjunct treatment for glaucoma and other ophthalmic surgeries.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Financials
- Market cap
- $1.4B
- Enterprise value
- $1.4B
Beyond the preview
Go deeper on Mobius Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mobius Therapeutics.